Cargando…

Cutaneous lesions in psoriatic arthritis are enriched in chemokine transcriptomic pathways

OBJECTIVES: Skin from people with psoriasis has been extensively studied and is assumed to be identical to skin from those with psoriatic arthritis (PsA). Chemokines and the CC chemokine scavenger receptor ACKR2 are upregulated in uninvolved psoriasis. ACKR2 has been proposed as a regulator of cutan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnsson, Hanna, Cole, John, Siebert, Stefan, McInnes, Iain B., Graham, Gerard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152590/ https://www.ncbi.nlm.nih.gov/pubmed/37131254 http://dx.doi.org/10.1186/s13075-023-03034-6

Ejemplares similares

Synovial Tissue Response to Treatment in Psoriatic Arthritis
por: Codullo, Veronica, et al.
Publicado: (2011)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Association of central adiposity with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional study of the UK Biobank
por: Ferguson, Lyn D, et al.
Publicado: (2019)

Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study
por: Ferguson, Lyn D, et al.
Publicado: (2021)

Macrophage dysfunction in Psoriatic Arthritis
por: Wenink, Mark H, et al.
Publicado: (2011)

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
por: Fragoulis, George E, et al.
Publicado: (2019)

Metatarsophalangeal joint pain in psoriatic arthritis: a cross-sectional study
por: Turner, Deborah E., et al.
Publicado: (2014)

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
por: McGonagle, Dennis G, et al.
Publicado: (2019)

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
por: Sweet, Kristen, et al.
Publicado: (2021)

Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis
por: Jongbloed, Sarah L, et al.
Publicado: (2006)

MicroRNA-155 regulates monocyte chemokine and chemokine receptor expression in Rheumatoid Arthritis
por: Elmesmari, Aziza, et al.
Publicado: (2016)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

The characterisation and regulation of type 1 immune responses in psoriatic arthritis
por: Gracie, JA, et al.
Publicado: (2002)

Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity – a cross-sectional study
por: Ferguson, Lyn D, et al.
Publicado: (2020)

Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis
por: Ooms, Alexander, et al.
Publicado: (2023)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis
por: Wenink, Mark H, et al.
Publicado: (2011)

Identification of Urinary Peptide Biomarkers Associated with Rheumatoid Arthritis
por: Stalmach, Angelique, et al.
Publicado: (2014)

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
por: Mease, Philip J., et al.
Publicado: (2020)

JAK inhibitors and infections risk: focus on herpes zoster
por: Sunzini, Flavia, et al.
Publicado: (2020)

Ustekinumab Treatment and Improvement of Physical Function and Health‐Related Quality of Life in Patients With Psoriatic Arthritis
por: Rahman, Proton, et al.
Publicado: (2016)

Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
por: McInnes, Iain B, et al.
Publicado: (2022)

The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis
por: Fragoulis, George E., et al.
Publicado: (2022)

Substantial Alterations of the Cutaneous Bacterial Biota in Psoriatic Lesions
por: Gao, Zhan, et al.
Publicado: (2008)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
por: Mease, Philip J, et al.
Publicado: (2017)

Chemokines and chemokine receptors expression in the lesions of patients with American cutaneous leishmaniasis
por: Díaz, Nilka Luisa, et al.
Publicado: (2013)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
por: McInnes, Iain B, et al.
Publicado: (2019)

Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome
por: Fragoulis, George E, et al.
Publicado: (2018)

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2022)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
por: Pournara, Effie, et al.
Publicado: (2021)

Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?
por: Siebert, Stefan, et al.
Publicado: (2019)

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2021)

Future therapeutic targets in rheumatoid arthritis?
por: Cheung, Tommy Tsang, et al.
Publicado: (2017)

IL-23 orchestrating immune cell activation in arthritis
por: Najm, Aurélie, et al.
Publicado: (2021)

Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study
por: Colaco, Keith, et al.
Publicado: (2022)

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
por: McInnes, Iain B, et al.
Publicado: (2017)

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study
por: McInnes, Iain B., et al.
Publicado: (2018)

Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features
por: Fragoulis, George E, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ou970ek64u4bfv7fu4vvnn8dsi